{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:26:45Z","timestamp":1717633605990},"reference-count":60,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Widespread screening for hepatitis C virus (HCV) is necessary for Canada to meet its HCV elimination goals by 2030. People who currently or previously injected drugs are at high risk for HCV. Opioid agonist therapy (OAT, such as methadone and buprenorphine) has been shown to help stabilize the lives of people who are opioid\u2010dependent. The distribution of OAT in North America typically requires daily, weekly, or monthly clinic visits and presents an opportunity for engagement, screening and treatment for those at high\u2010risk of HCV. In this study, HCV screening was conducted by staff at OAT clinics in Ontario from 2016 to 2020 and those with chronic infections were treated on\u2010site with direct\u2010acting antivirals. Point\u2010of\u2010care or dried blood spot (DBS) testing was used for antibodies, DBS or serum for HCV RNA and serum for HCV RNA at SVR12 (sustained virological response). Clinics screened 1954 people (mean age 40\u2009years \u00b112, 63% male). Forty\u2010five percent were antibody positive, of whom 64% were HCV RNA+. Eighty percent of those RNA+ set an appointment in which 99% attended. Ninety\u2010six percent started treatment with 87% completing treatment. Sixty\u2010eight percent of people who completed treatment submitted a sample for SVR12 testing of which 97% achieved a virological cure. Results suggest that HCV screening and treatment at OAT clinics is feasible, effective and warrants expansion. Data suggest strong treatment adherence due to high rates of SVR12 comparable with other OAT\u2010based HCV treatment programs. The lack of SVR12 sampling could be addressed by either on\u2010site phlebotomy or incentivizing SVR12 sampling.<\/jats:p>","DOI":"10.1111\/jvh.13931","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T15:23:04Z","timestamp":1708615384000},"page":"240-247","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada"],"prefix":"10.1111","volume":"31","author":[{"given":"B.","family":"Wolfson\u2010Stofko","sequence":"first","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"},{"name":"Center for Drug Use and HIV\/HCV Research (CDUHR), College of Global Public Health New York University  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hirode","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vanderhoff","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Karkada","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Capraru","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Biondi","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"},{"name":"School of Nursing York University  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"},{"name":"Division of Gastroenterology &amp; Hepatology Erasmus Medical Center  Rotterdam The Netherlands"},{"name":"Department of Epidemiology, Biostatistics Erasmus MC University Medical Center  Rotterdam the Netherlands"},{"name":"Institute of Health Policy, Management, and Evaluation University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Shah","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L. A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"},{"name":"Division of Gastroenterology &amp; Hepatology Erasmus Medical Center  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Feld","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease University Health Network  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v47i12a01"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044103"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.1.2.005"},{"key":"e_1_2_8_5_1","volume-title":"Hepatitis C in Ontario, 2018: Surveillance Summary One Year after a Case Definition Update","author":"Ontario Agency for Health Protection and Promotion (Public Health Ontario)","year":"2020"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00161.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03765.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103439"},{"key":"e_1_2_8_9_1","unstructured":"Ontario Ministry of Health and Long\u2010Term Care.Ontario Drug Benefit Formulary\/Comparative Drug Index Summary of Changes\u2013February 2018. In: Drug Programs Policy and Strategy Branch Ontario Public Drug Programs editor. Toronto ON.2018."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170453"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30075-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20160008"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ948"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2002.10625.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/001789690306200307"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-8-35"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdv143"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.01.037"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.0.0088"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826081003659543"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.018"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3799-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14608"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03749.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13949"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00399-8"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12600-1"},{"issue":"3","key":"e_1_2_8_28_1","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"Mattick RP","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12682"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5416"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02188.x"},{"key":"e_1_2_8_33_1","volume-title":"Buprenorphine\/Naloxone for Opioid Dependence: Clinical Practice Guideline","author":"Handford C","year":"2012"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0816"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw579"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1715"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz696"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa105"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa612"},{"key":"e_1_2_8_40_1","unstructured":"MurphyG FarahB WongW et\u00a0al.CADTH Therapeutic Reviews. Direct\u2010Acting Antiviral Agents for Chronic Hepatitis C Genotype 1. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health2014."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20160161"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13223"},{"issue":"10","key":"e_1_2_8_43_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163488","article-title":"Cost\u2010effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands","volume":"11","author":"Santen DK","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14731"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz384"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15756"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15630"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.025"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30404-1"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11608-9"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13600"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-020-00286-2"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz693"},{"key":"e_1_2_8_54_1","unstructured":"Health Canada.Safer Supply Ottawa ON 2021. Available from:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/opioids\/responding\u2010canada\u2010opioid\u2010crisis\/safer\u2010supply.html"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.0109"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.03.012"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003410.pub4"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717711167"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy899"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30676-X"},{"issue":"4","key":"e_1_2_8_61_1","first-page":"493","article-title":"Timing of elimination of hepatitis C virus in Canada's provinces","volume":"5","author":"Feld JJ","year":"2022","journal-title":"Can Liver J"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:12:43Z","timestamp":1717582363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/jvh.13931"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13931","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"2023-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}